Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.

This study investigated whether the second-generation translocator protein 18kDa (TSPO) radioligand, [18F]-FEPPA, could be used in neurodegenerative parkinsonian disorders as a biomarker for detecting neuroinflammation in the striatum. Neuroinflammation has been implicated as a potential mechanism f...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuko Koshimori, Ji-Hyun Ko, Romina Mizrahi, Pablo Rusjan, Rostom Mabrouk, Mark F Jacobs, Leigh Christopher, Clement Hamani, Anthony E Lang, Alan A Wilson, Sylvain Houle, Antonio P Strafella
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0138721&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850162307160604672
author Yuko Koshimori
Ji-Hyun Ko
Romina Mizrahi
Pablo Rusjan
Rostom Mabrouk
Mark F Jacobs
Leigh Christopher
Clement Hamani
Anthony E Lang
Alan A Wilson
Sylvain Houle
Antonio P Strafella
author_facet Yuko Koshimori
Ji-Hyun Ko
Romina Mizrahi
Pablo Rusjan
Rostom Mabrouk
Mark F Jacobs
Leigh Christopher
Clement Hamani
Anthony E Lang
Alan A Wilson
Sylvain Houle
Antonio P Strafella
author_sort Yuko Koshimori
collection DOAJ
description This study investigated whether the second-generation translocator protein 18kDa (TSPO) radioligand, [18F]-FEPPA, could be used in neurodegenerative parkinsonian disorders as a biomarker for detecting neuroinflammation in the striatum. Neuroinflammation has been implicated as a potential mechanism for the progression of Parkinson's disease (PD). Positron Emission Tomography (PET) radioligand targeting for TSPO allows for the quantification of neuroinflammation in vivo. Based on genotype of the rs6791 polymorphism in the TSPO gene, 16 mixed-affinity binders (MABs) (8 PD and age-matched 8 healthy controls (HCs)), 16 high-affinity binders (HABs) (8 PD and age-matched 8 HCs) and 4 low-affinity binders (LABs) (3 PD and 1 HCs) were identified. Total distribution volume (VT) values in the striatum were derived from a two-tissue compartment model with arterial plasma as an input function. There was a significant main effect of genotype on [18F]-FEPPA VT values in the caudate nucleus (p = 0.001) and putamen (p < 0.001), but no main effect of disease or disease x genotype interaction in either ROI. In the HAB group, the percentage difference between PD and HC was 16% in both caudate nucleus and putamen; in the MAB group, it was -8% and 3%, respectively. While this PET study showed no evidence of increased striatal TSPO expression in PD patients, the current findings provide some insights on the possible interactions between rs6791 polymorphism and neuroinflammation in PD.
format Article
id doaj-art-71fb6f322fac47f39473fe5d0818ecf0
institution OA Journals
issn 1932-6203
language English
publishDate 2015-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj-art-71fb6f322fac47f39473fe5d0818ecf02025-08-20T02:22:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01109e013872110.1371/journal.pone.0138721Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.Yuko KoshimoriJi-Hyun KoRomina MizrahiPablo RusjanRostom MabroukMark F JacobsLeigh ChristopherClement HamaniAnthony E LangAlan A WilsonSylvain HouleAntonio P StrafellaThis study investigated whether the second-generation translocator protein 18kDa (TSPO) radioligand, [18F]-FEPPA, could be used in neurodegenerative parkinsonian disorders as a biomarker for detecting neuroinflammation in the striatum. Neuroinflammation has been implicated as a potential mechanism for the progression of Parkinson's disease (PD). Positron Emission Tomography (PET) radioligand targeting for TSPO allows for the quantification of neuroinflammation in vivo. Based on genotype of the rs6791 polymorphism in the TSPO gene, 16 mixed-affinity binders (MABs) (8 PD and age-matched 8 healthy controls (HCs)), 16 high-affinity binders (HABs) (8 PD and age-matched 8 HCs) and 4 low-affinity binders (LABs) (3 PD and 1 HCs) were identified. Total distribution volume (VT) values in the striatum were derived from a two-tissue compartment model with arterial plasma as an input function. There was a significant main effect of genotype on [18F]-FEPPA VT values in the caudate nucleus (p = 0.001) and putamen (p < 0.001), but no main effect of disease or disease x genotype interaction in either ROI. In the HAB group, the percentage difference between PD and HC was 16% in both caudate nucleus and putamen; in the MAB group, it was -8% and 3%, respectively. While this PET study showed no evidence of increased striatal TSPO expression in PD patients, the current findings provide some insights on the possible interactions between rs6791 polymorphism and neuroinflammation in PD.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0138721&type=printable
spellingShingle Yuko Koshimori
Ji-Hyun Ko
Romina Mizrahi
Pablo Rusjan
Rostom Mabrouk
Mark F Jacobs
Leigh Christopher
Clement Hamani
Anthony E Lang
Alan A Wilson
Sylvain Houle
Antonio P Strafella
Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.
PLoS ONE
title Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.
title_full Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.
title_fullStr Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.
title_full_unstemmed Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.
title_short Imaging Striatal Microglial Activation in Patients with Parkinson's Disease.
title_sort imaging striatal microglial activation in patients with parkinson s disease
url https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0138721&type=printable
work_keys_str_mv AT yukokoshimori imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT jihyunko imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT rominamizrahi imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT pablorusjan imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT rostommabrouk imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT markfjacobs imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT leighchristopher imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT clementhamani imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT anthonyelang imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT alanawilson imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT sylvainhoule imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease
AT antoniopstrafella imagingstriatalmicroglialactivationinpatientswithparkinsonsdisease